Endothelial function assessment by positron emission tomography in patients with hypercholesterolemia;Estudio de la función endotelial mediante tomografía por emisión de positrones en pacientes con hipercolesterolemia

Archivos de Cardiologia de Mexico

Volumn 78, Issue 2, 2008, Pages 139-147

  Rosas, Erick Alexánderson ^a,b   González, Aloha Meave ^a,b   Castillo, Leonardo García Rojas ^a   Valero, Mónica Rodríguez ^a   Molina, Pedro Alberto Lamothe ^a   Petra, José Antonio Talayero ^a   Fernández, Carlos Sierra ^a   García Villa, Patricio Cruz ^a   Zanella, Hugo Gerardo Rodríguez ^a   Pérez, María Barrera ^a   Cerón, Rocío Elisa Carrera ^a   Torres, Rodrigo Calleja ^a   García, Alfonso Martínez ^a   Alcocer, Alejandro Ricalde ^b   Ibarra, José Luis Romero ^a   Rosas, Graciela Alexánderson ^c  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^c HOSPITAL GENERAL DE MÉXICO   (Mexico)

Author keywords

Dyslipidemia; Endothelial dysfunction; Positron emission tomography

Indexed keywords

ADENOSINE; AMMONIA N 13;

ADULT; ARTICLE; CLINICAL ARTICLE; COLD PRESSOR TEST; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY FLOW RESERVE; ENDOTHELIUM; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MALE; POSITRON EMISSION TOMOGRAPHY;

ADULT; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES;

EID: 46749143404     PISSN: 14059940     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Encuesta Nacional de Salud 2006. Secretaría de Salud. México.
2. KANNEL WB: The Framingham Study: ITS 50-year legacy and future promise. J Atheroscler Thromb 2000; 6(2): 60-66.
3. WILSON PWF, D'AGOSTINO RB, LEVY D, BELANGER AM, SILBERSHATZ H, KANNEL WB: Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-1847.
4. STAMLER J, WENTWORTH D, NEATON JD, for the MRFIT Research Group: Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986; 256: 2823-2828.
5. The Lipid Research Clinics Coronary Primary Prevention Trial results. I: Reduction in the incidence of coronary heart disease. JAMA 1984; 251(3): 351-64.
6. MCGILL HC JR: Introduction to the geographic pathology of atherosclerosis. Lab Invest 1968; 18: 465-467.
7. KEYS A, MENOTTI A, ARAVANIS C, BLACKBURN H, DJORDJEVIC BS, BUZINA R, ET AL: The Seven Countries Study: 2,289 deaths in 15 years. Prev Med 1984; 13: 141-54.
8. BROWN MS, GOLDSTEIN JL: A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232: 34-47.
9. Third report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Adult Treatment Panel III.
10. MENOTTI A, KEYS A, BLACKBURN H, KROMHOUT D, KARVONEN M, NISSINEN A, ET AL: Comparison of multivariate predictive power of major risk factors for coronary heart diseases in different countries: results from eight nations of the Seven Countries Study, 25-year follow-up. J Cardiovasc Risk 1996; 3(1): 69-75.
11. LAW MR, WALD NJ, THOMPSON SG: By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994; 308: 367-72.
12. LAW MR: Lowering heart disease risk with cholesterol reduction: evidence from observational studies and clinical trials. Eur Heart J 1999; 1: S3-S8.
13. WILSON PWF, D'AGOSTINO RB, LEVY D, BELANGER AM, SILBERSHATZ H, KANNEL WB: Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-1847.
14. GORDON DJ, PROBSTFIELD JL, GARRISON RJ, NEATON JD, CASTELLI WP, KNOKE JD, ET AL: High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 1989; 79: 8-15.
15. ABBOTT RD, DONAHUE RP, KANNEL WB, WILSON PW: The impact of diabetes on survival following myocardial infarction in men vs women: the Framingham Study. JAMA 1988; 260: 3456-3460.
16. VAN LENTEN BJ, HAMA SY, DE BEER FC, STAFFORINI DM,MCINTYRE TM, PRESCOTT SM, ET AL: Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response: loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995; 96: 2758-2767.
17. NAVAB M, HAMA SY, ANANTHARAMAIAH GM, HASSAN K, HOUGH GP, WATSON AD, ET AL: Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res 2000; 41: 1495-1508.
18. NAVAB M, HAMA SY, COOKE CJ, ANANTHARAMAIAH GM, CHADDHA M, JIN L, ET AL: Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res 2000; 41: 1481-1494.
19. KLAG MJ, FORD DE, MEAD LA, HE J, WHELTON PK, LIANG K-Y, LEVINE DM: Serum cholesterol in young men and subsequent cardiovascular disease. N Engl J Med 1993; 328: 313-80.
20. STAMLER J, DAVIGLUS ML, GARSIDE DB, DYER AR, GREENLAND P, NEATON JD: Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-causemortality and to longevity. JAMA 2000; 284: 311-318.
21. BREUER H: Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin. Curr Med Res Opin 2001; 17(1): 60-73.
22. GOTTO AM: Triglyceride as a risk factor for coronary artery disease. Am J Cardiol 1998; 82(9A): 22Q-25Q.
23. CZERNIN J, BARNARD RJ, SUN KT, KRIVOKAPICH J, NITZSCHE E, DORSEY D, ET AL: Effect of shot-term cardiovascular conditioning and low-fat diet on myocardial blood flow and flow reserve. Circulation 1995; 92: 197-204.
24. PITKÄNEN OP, RAITAKARI OT, NIINIKOSKI H, NUUTILA P, IIDA H, VOIPIO-PULKKI LM, ET AL: Coronary flow reserve is impaired in young men with familial hypercholesterolemia. J Am Coll Cardiol 1996; 28: 1705-1711.
25. YOKOYAMA I, OHTAKE T, MOMAMURA S, NISHIKAWA J, SASAKI Y, OMATA M: Reduced coronary flow reserve in hypercholesterolemic patients without overt coronary stenosis. Circulation 1996; 94: 3232-3238.
26. DAYANIKLI F, GRAMBOW D, MUZIK O, MOSCA L, RUBENFIRE M, SCHWAIGER M: Early detection of abnormal coronary flow reserve in asymptomatic men at high risk for coronary artery disease using positron emission tomography. Circulation 1994; 90: 808-817.
27. ZEIHER AM, DREXLER H, WOLLSCHLAGER H, JUST H: Endothelial dysfunction of the coronary microvasculature is associated with impaired coronary blood flow regulation inpatients with early atherosclerosis. Circulation 1991; 84: 1484-1492.
28. SEILER C, HESS OM, BUECHI M, SUTER TM, KRAYENBUEHL HP: Influence of serum cholesterol and other coronary risk factors on vasomotion of angiographically normal coronary arteries. Circulation 1993; 88: 2139-2148.
29. ENGLER MM, ENGLER MB, MALLOY MJ, CHIU EY, SCHLOETTER MC, PAUL SM, ET AL: Antioxidant vitamins C and E improve endothelial function in children with hyperlipidemia: Endothelial Assessment of Risk from Lipids in Youth (EARLY) Trial. Circulation 2003; 108: 1059-1063.
30. TANNER FC, NOLL G, BOULANGER CM, LUSCHER TF: Oxidized low density lipoproteins inhibit relaxations of porcine coronary arteries: role of scavenger receptor and endothelium-derived nitric oxide. Circulation 1991; 83: 2012-2020.
31. HEIN WH, KUO L: LDLs impair vasomotor function of the coronary microcirculation: role of superoxide anions. Circ Res 1998; 83: 404-414.
32. PITKANEN OP, NUUTILA P, RAITAKARI OT, RÖNNEMAA T, KOSKINEN PJ, IIDA H, ET AL: Coronary flow reserve is reduced in young men with IDDM. Diabetes 1998; 47: 248-54.
33. DI CARLI MF, BIANCO-BATLLES D, LANDA ME, KAZMERS A, GROEHN H, MUZIK O, ET AL: Effects of autonomic neuropathy on coronary blood flow in patients with diabetes mellitus. Circulation 1999; 100: 813-9.
34. TADDEI S, VIRDIS A, MATTEI P, GHIADONI L, SUDANO I, SALVETTI A: Defective L-arginine-nitric oxide pathway in offspring of essential hypertensive patients. Circulation 1996; 94: 1298-1303.
35. LANDMESSER U, HORNING B, DREXLEER H: Endothelyal dysfunction in hypercholesterolemia: Mechanism, patophysiological importance and therapeutic interventions. Semin Thromb Hemost 2000; 26: 529-538.
36. 15O]water techniques. Circulation 1996; 93: 2000-2006.
37. DE SILVA R, CAMICI PG: The role of positron emission tomography in the investigation of coronary circulatory function in man. Cardiovasc Res 1994; 28: 1595-1612.
38. SAWADA S, MUZIK O, BEANLNADS R, WOLFE E, HUTCHINGS G, SCHWAIGER M: Interobserver and inter study variability of myocardial blood flow an flow-reserve measurements with nitrogen-13-ammonia labele positron emission tomography. J Nucl Cardiol 1995; 2: 413-422.
39. ZEIHER AM, DREXLER H, WOLLSCHLÄGER H, JUST H: Endothelial dysfunction of the coronary microvasculature is associated with impaired coronary blood flow regulation in patients with early atherosclerosis. Circulation 1991; 84: 1984-1992.
40. ALEXANDERSON E, ROMERO J, RICALDE A, ALEXANDERSON G, MEAVE A: Assessment of endothelial function by positron emission tomography. Current Cardiology Reviews 2006; 2: 101-107.
41. ZEIHER AM, DREXLER H, WOLLSCHLAEGER H, SAURBIER B, JUST H: Coronary vasomotion in response to sympathetic stimulation in humans: importance of the functional integrity of the endothelium. J Am Coll Cardiol 1989; 14: 1181-1190.
42. SCHELBERT H, WISENBERG G, PHELPS ME, GOULD KL, HENZE E, HOFFMAN EJ, ET AL: Noninvasive assessment of coronary stenoses by myocardial imaging during pharmacologic coronary vasodilation, VI: detection of coronary artery disease in man with intravenous 13-NH3 and positron computed tomography. Am J Cardiol 1982; 49: 1197-1207.
43. KAUFMANN P, GNECCHI-RUSCONE T, SCHÄFERS KP, LÜSCHER TF, CAMICI PG: Low Density Lipoprotein Cholesterol and Coronary Microvascular Dysfunction in Hypercholesterolemia. J Am Coll Cardiol 2000; 36: 103-109.
44. PITKÄNEN O-P, NUUTILA P, RAITAKARI O, PORKKA K, IIDA H, NUOTIO I, ET AL: Coronary Flow Reserve in Young Men With Familial Combined Hyperlipidemia. Circulation 1999; 99(13): 1678-1684.
45. YOKOYAMA I, YONEKURA K, INOUE Y, OHTOMO K, NAGAI R: Long-term effect of simvastatin on the improvement of impaired myocardial flow reserve in patients with familial hypercholesterolemia without gender variant. J Nucl Cardiol 2001; 8(4): 445-51.
46. YOKOYAMA I, MURAKAMI T, OHTAKE T, MOMOMURA S, NISHIKAWA J, SASAKI Y, OMATA M: Reduced coronary flow reserve in familial hypercholesterolemia. J Nucl Med 1996; 37(12): 1937-42.
47. PITKÄNEN O-P, RAITAKARI OT, RÖNNEMAA T, NIINIKOSKI H, NUUTILA P, IIDA H, ET AL: Influence of cardiovascular risk status on coronary flow reserve in healthy young men. Am J Cardiol 1997; 79: 1690-1692.
48. RAITAKARI OT, PITKÄNEN O-P, LEHTIMÄ KI T, LAHDENPERÄ S, IIDA H, YLÄ- HERTTUALA S, ET AL: In vivo low density lipoprotein oxidation relates to coronary reactivity in young men. J Am Coll Cardiol 1997; 30: 97-102.
49. GOULD KL, MARTUCCI JP, GOLDBERG DI, HESS MJ, EDENS RP, LATIFI R, ET AL: Short-term cho lesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. Circulation 1994; 89: 1530-1538.
50. CZERNIN J, BARNARD RJ, SUN KT, KRIVOKAPICH J, NITZSCHE E, DORSEY D, ET AL: Effect of short-term cardiovascular conditioning and low-fat diet on myocardial blood flow and flow reserve. Circulation 1995; 92: 197-204,
51. GUETHLIN M, KASEL AM, COPPENRATH K, ZIEGLER S, DELIUS W, SCHWAIGER M: Delayed response of myocardial flow reserve to lipidlowering therapy with fluvastatin. Circulation 1999; 99: 475- 481.
52. BALLER D, NOTOHAMIPRODJO G, GLEICHMANN U, HOLZINGER J, WEISE R, LEHMANN J: Improvement in Coronary Flow Reserve Determined by Positron Emission Tomography After 6 Months of Cholesterol-Lowering Therapy in Patients With Early Stages of Coronary Atherosclerosis. Circulation 1999; 99: 2871-2875.
53. SACKS FM, TONKIN AM, SHEPHERD J, BRAUNWALD E, COBBE S, HAWKINS CM, ET AL, for the Prospective Pravastatin Pooling Project Investigators Group: Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation 2000; 102: 1893-1900.
54. WIENHARD K, DAHLBOM M, ERIKSSON L, MICHEL C, BRUCKBAUER T, PIETRZYK U, ET AL: The ECAT EXACT HR: performance of a new high resolution positron scanner. J Comput Assist Tomogr 1994; 18: 110-118.
55. 13N]ammonia and reoriented dynamic positron emission tomographic imaging. Circulation 1992; 86: 1004-1017.
56. CAMPISI R, DI CARLI M: Assessment of coronary flow reserve and microcirculation: A clinical perspective. J Nucl Cardiol 2004; 11: 3-11.
57. MCLENACHAN JM, VITA J, FISH DR, TEASURE CB, COX DA, GANZ P, ET AL: Early evidence of endothelial vasodilator dysfunction at coronary branching points. Circulation 1990; 82: 1169-1173.
58. ZEIHER AM, DREXLER H, WOLLSCHLÄGER H, JUST H: Modulation of coronary vasomotor tone in humans: progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation 1991; 83: 391-401.
59. HALCOX JPJ, SCHENKE WH, ZALOS G, MINCEMOYER R, PRASAD A, WACLAWIW MA, ET AL: Prognostic value of coronary vascular endothelial dysfunction. Circulation. 2002; 106: 653-658.
60. SCHÄCHINGER V, BRITTEN MB, ZEIHER AM: Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101: 1899-1906.